Brief: Autolus Therapeutics Receives EMA Orphan Medical Product Designation For Obe-Cel For Treatment Of Acute Lymphoblastic Leukemia
31/03/2022 12:55
March 31 (Reuters) - Autolus Therapeutics PLC AUTL.O :
* AUTOLUS THERAPEUTICS RECEIVES EMA ORPHAN MEDICAL PRODUCT
DESIGNATION FOR OBE-CEL FOR TREATMENT OF ACUTE LYMPHOBLASTIC
LEUKEMIA
Source text for Eikon: ID:nGNX9NlKrt
Further company coverage: AUTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Autolus Therapeutics
See all newsBrief: Autolus Therapeutics PLC Unit Enters Master Service Agreement With AGC Biologics
Brief: Autolus Therapeutics Appoints Ryan Richardson To Board Of Directors
Brief: Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia
Brief: Autolus Therapeutics’ Car T Therapy Aucatzyl® (Obecabtagene Autoleucel) Granted European Marketing Authorization For Adult Patients
Brief: Autolus Therapeutics Announces Inducement Grants